csxb8k02082010.htm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NO.: 1-08397
Date of Report: February 4, 2010
(Exact name of registrant as specified in its charter)
| Nevada |
95-4755369 |
| (State of other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
| 49 Fuxingmennei Street, Suite 310, Beijing, P.R. China |
100031 |
| (Address of principal executive offices) |
(Zip Code) |
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 |
Departure of Directors |
Effective on February 4, 2010, Feng Zhenxing and Feng Guowu have resigned from their positions as members of the Registrant’s Board of Directors. Chen Yu remains the only member of the Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
February 8, 2010 CHINA
SXAN BIOTECH, INC.
By: /s/ Chen Yu
Chen Yu, Chief Executive Officer